Comorbidities of sarcoidosis

Autor: Claudio Tana, Marjolein Drent, Hilario Nunes, Vasilis Kouranos, Francesco Cinetto, Naomi T. Jessurun, Paolo Spagnolo

Publikováno v: Annals of Medicine, Vol 54, Iss 1, Pp 1014-1035 (2022)

Sarcoidosis is a heterogeneous disease, which can affect virtually every body organ, even though lungs and intra thoracic lymph nodes are almost universally affected. The presence of noncaseating granulomas is the histopathological hallmark of the di

Externí odkaz: https://doaj.org/article/c98169e4726b4836aea4a2c936797d86

Sex differences in adverse drug reactions from Adalimumab and etanercept in patients with inflammatory rheumatic diseases

Autor: Helen R. Gosselt, Jette A. van Lint, Leanne J. Kosse, Phyllis I. Spuls, Harald E. Vonkeman, Sander W. Tas, Frank Hoentjen, Michael T. Nurmohamed, Bart J.F. van den Bemt, Martijn B.A. van Doorn, Naomi T. Jessurun

Publikováno v: Expert Opinion on Drug Safety. Taylor & Francis Ltd
Gosselt, H R, van Lint, J A, Kosse, L J, Spuls, P I, Vonkeman, H E, Tas, S W, Hoentjen, F, Nurmohamed, M T, van den Bemt, B J F, van Doorn, M B A & Jessurun, N T 2023, ' Sex differences in adverse drug reactions from Adalimumab and etanercept in patients with inflammatory rheumatic diseases ', Expert opinion on drug safety . https://doi.org/10.1080/14740338.2023.2181340
Expert opinion on drug safety. Taylor & Francis
Expert opinion on drug safety. Taylor and Francis Ltd.

Background: We examine sex differences in relation to the nature, frequency, and burden of patient-reported adverse drug reactions (ADRs) in patients with inflammatory rheumatic diseases. Research design and methods: Rheumatoid arthritis, psoriatic a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc607e4de4e5ca6c882d4814677a707a
https://pure.eur.nl/en/publications/ded233d7-47b1-4304-88a5-3c9d87d47e17

Hypoglycaemia following JAK inhibitor treatment in patients with diabetes

Autor: Jette A van Lint, Florence P A M van Hunsel, Sander W Tas, Harald E Vonkeman, Frank Hoentjen, Martijn B A van Doorn, Renske C F Hebing, Michael T Nurmohamed, Bart J F van den Bemt, Eugene P van Puijenbroek, Naomi T Jessurun

Publikováno v: Annals of the Rheumatic Diseases, 81(4), 597-599. BMJ PUBLISHING GROUP
Annals of the Rheumatic Diseases, 81(4), 597-599. BMJ Publishing Group
Annals of the Rheumatic Diseases, 81, 4, pp. 597-599
Annals of the rheumatic diseases, 81, 597-599. BMJ
Annals of the rheumatic diseases, 81(4):annrheumdis-2021-221840, 597-599
Annals of the Rheumatic Diseases, 81, 597-599
van Lint, J A, van Hunsel, F P A M, Tas, S W, Vonkeman, H E, Hoentjen, F, van Doorn, M B A, Hebing, R C F, Nurmohamed, M T, van den Bemt, B J F, van Puijenbroek, E P & Jessurun, N T 2022, ' Hypoglycaemia following JAK inhibitor treatment in patients with diabetes ', Annals of the Rheumatic Diseases, vol. 81, no. 4, pp. 597-599 . https://doi.org/10.1136/annrheumdis-2021-221840
Annals of the rheumatic diseases, 81(4), 597-599. BMJ Publishing Group

Contains fulltext : 249098.pdf (Publisher’s version ) (Closed access)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::404c4f6b02c2d1f536cc6ea43c99da88
https://doi.org/10.1136/annrheumdis-2021-221840

Immune-mediated inflammatory disease patients’ preferences in adverse drug reaction information regarding biologics

Autor: Eugène van Puijenbroek, Frank Hoentjen, Phyllis I. Spuls, Martijn B. A. van Doorn, Bart J F van den Bemt, Michael T. Nurmohamed, G. Weits, L. Kosse, Naomi T Jessurun, Harald E. Vonkeman, Sander W. Tas

Publikováno v: Expert Opinion on Drug Safety, 19, 8, pp. 1049-1054
Expert Opinion on Drug Safety, 19(8), 1049-1054. Taylor & Francis Ltd
Expert opinion on drug safety, 19(8), 1049-1054. Taylor & Francis
Kosse, L J, Weits, G, Vonkeman, H E, Spuls, P I, Van Den Bemt, B J F, Tas, S W, Hoentjen, F, Nurmohamed, M T, Van Doorn, M B A, Van Puijenbroek, E P & Jessurun, N T 2020, ' Immune-mediated inflammatory disease patients' preferences in adverse drug reaction information regarding biologics ', Expert opinion on drug safety, vol. 19, no. 8, pp. 1049-1054 . https://doi.org/10.1080/14740338.2020.1781090
Expert Opinion on Drug Safety, 19, 1049-1054
Expert opinion on drug safety, 19(8), 1049-1054. Taylor and Francis Ltd.
Expert opinion on drug safety, 1-5. Taylor and Francis Ltd.
STARTPAGE=1;ENDPAGE=5;ISSN=1474-0338;TITLE=Expert opinion on drug safety

OBJECTIVES: Patient-reported outcomes (PROs) are increasingly used in studies and medical practice to obtain information on patients' perspectives toward their treatment or disease. However, most study outcomes are primarily directed at healthcare pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d526eba6c4953f10dc4074834d38b923
https://doi.org/10.1080/14740338.2020.1781090

Ranking Self-reported Gastrointestinal Side Effects of Pharmacotherapy in Sarcoidosis

Autor: Aalt Bast, Naomi T Jessurun, V. L. J. Proesmans, S M G de Jong, Marjolein Drent, N M Ebner, Marjon Elfferich, E D O Lewis

Publikováno v: Lung
Lung, 198(2), 395-403. Springer, Cham

Background Clinical manifestations of sarcoidosis vary widely, depending on the intensity of the inflammation and the organ systems affected. So far, no curative treatment exists; the disease can only be suppressed. All treatment options cause side e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f27d996b209d7703581113636b35433
https://cris.maastrichtuniversity.nl/en/publications/d8cce412-3da5-408e-ac39-4a79cbaf764e